Last reviewed · How we verify
Treatment C: abiraterone acetate
At a glance
| Generic name | Treatment C: abiraterone acetate |
|---|---|
| Also known as | ZYTIGA |
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- fatigue
- Musculoskeletal pain
- Increased Hemoglobin
- Hypertension
- nausea
- Anemia
- Breast Tenderness
- rash
- hot flashes
- cough
- gynecomastia
- pruritis
Key clinical trials
- A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer (PHASE1)
- Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial (PHASE2)
- Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (PHASE1, PHASE2)
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial (PHASE2)
- A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer (PHASE3)
- Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer (PHASE2)
- A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer (PHASE3)
- A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: